TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Problems
Hormone replacement therapy and breast disease
Key Statistics
- 1 in 9 — UK lifetime breast cancer risk
- RR 1.35 — Combined HRT >5yr use (1997 re-analysis)
- 4–5× — Risk with biopsy-proven atypia
Don't-miss facts
-
Progestogen – not estrogen – drives the added breast cancer risk with HRT
-
Unopposed estrogen ≤5yr: no increase in diagnosis risk (CEE and estradiol valerate similar, any route)
-
Combined HRT: risk emerges after 3 years (WHI); RR 1.35 for >5yr use (1997 re-analysis)
-
LNG-IUS is NOT risk-free as HRT progestogen component – case-control data show increased risk
-
Only biopsy-proven atypia raises risk from benign breast disease: 4–5×
-
BRCA1 lifetime risk 44–78%; BRCA2 31–56%; familial disease = ~10% of cases; HRT does not add to this baseline risk
-
HABITS, Stockholm, national UK trial, LIBERATE all closed prematurely – HABITS & LIBERATE (tibolone, ER+ve) showed increased recurrence
-
No robust evidence HRT worsens breast cancer survival overall – MWS 22% mortality increase is the outlier and methodologically flawed
Risk at a glance
Unopposed estrogen ≤5yr: no significant ↑risk Combined HRT >3yr / LNG-IUS / synthetic progestogens: ↑risk
Abbreviation Key
- HRT — hormone replacement therapy
- BRCA1/2 — breast cancer susceptibility gene 1/2
- WHI — Women’s Health Initiative
- HABITS — Hormonal replacement therapy After Breast cancer—Is IT Safe? trial
- MWS — Million Women Study
- LIBERATE — Livial Intervention following Breast cancer: Efficacy,
- CEE — conjugated equine estrogen Recurrence, And Tolerability study
- LNG-IUS — levonorgestrel-releasing intrauterine system
- RR — relative risk
- ER+ve/ER−ve — estrogen receptor-positive/negative
- EMBRACE — Epidemiological Study of Familial Breast Cancer
- NICE — National Institute for Health and Clinical Excellence (Cancer Research UK)
Source: Marsden J. Hormone replacement therapy and breast disease. The Obstetrician & Gynaecologist 2010;12:155–163. doi:10.1576/toag.12.3.155.27597
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).